Neurotech International Limited announced that it has filed its first strategic provisional patent applications with IP Australia to underpin future world-wide patent families in respect to research conducted into the novel neuro-regulatory and anti-inflammatory properties of the NTI/Dolce medicinal cannabis strains. The two patents have been lodged to cover Uniqueness of the NTI-164 strain ­ composition profile with low THC (<0.3%) and a unique combination of `rarer' cannabinoids, and The application, formulation and use of the strain in relation to the treatment of a broad range of neuro-inflammatory disorders both on its own and in conjunction with current broadly available treatment options - `combination treatment therapies'.